|
Dec 9
|
3 Dividend Stocks Trading at 52-Week Lows
|
|
Dec 9
|
Is Pfizer (NYSE:PFE) Using Too Much Debt?
|
|
Dec 8
|
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
|
|
Dec 8
|
10 Cheap Dividend Stocks with High Yields
|
|
Dec 8
|
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
|
|
Dec 8
|
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
|
|
Dec 8
|
Zacks Market Edge Highlights: SAIC, ANET, LLY, PFE and SIG
|
|
Dec 7
|
Will There Be a Recession in 2024?
|
|
Dec 7
|
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
|
|
Dec 6
|
Pfizer CEO slams presidents of elite colleges over ‘despicable’ antisemitism
|
|
Dec 6
|
Pfizer (PFE) Declines More Than Market: Some Information for Investors
|
|
Dec 6
|
UPDATE 4-AbbVie to buy drug developer Cerevel for $8.7 billion
|
|
Dec 6
|
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
|
|
Dec 6
|
Column: A bogus new attack on COVID vaccines from Texas' least credible politician
|
|
Dec 5
|
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
|
|
Dec 5
|
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
|
|
Dec 5
|
Pfizer’s Weight-Loss Pill Disappointment Is an Opening for Biotech Rivals
|
|
Dec 5
|
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
|
|
Dec 5
|
12 Best Healthcare Dividend Stocks To Buy Now
|
|
Dec 5
|
Pfizer, after delay, completes enrollment in Lyme vaccine trial
|